All the above-described research findings taken together stimulated the idea to investigate whether inhibition of p38 MAPK with a specific small molecule inhibitor may have beneficial efficacy as a subacute phase stroke treatment via promoting functional recovery through blocking the deleterious effects of IL-1β on BDNF action and production, and with it on synaptic plasticity. Here, IL1B is linked to stroke disorder.